Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG, Zhong Y, Swami U, Briggs A, Young J, Feng Y, Song Y, Signorovitch J, Adejoro O, Chakravarty A, Chen M, Perini RF, Geynisman DM.
Bensimon AG, et al.
Curr Med Res Opin. 2020 Sep;36(9):1507-1517. doi: 10.1080/03007995.2020.1799771. Epub 2020 Aug 8.
Curr Med Res Opin. 2020.
PMID: 32697113
Free article.